Total synthesis of the indolizidine alkaloid tashiromine
Stephen P Marsden* and Alison D McElhinney

Address: School of Chemistry, University of Leeds, Leeds LS2 9JT, UK
Email: Stephen P Marsden* - s.p.marsden@leeds.ac.uk; Alison D McElhinney - alison.mcelhinney@camb-biotech.com
* Corresponding author

Abstract

Background: Tashiromine 1 is a naturally occurring indolizidine alkaloid. It has been the subject of thirteen successful total syntheses to date. Our own approach centres on the stereoselective construction of the indolizidine core by capture of an electrophilic acyliminium species by a pendant allylsilane. The key cyclisation precursor is constructed using olefin cross-metathesis chemistry, which has the potential to facilitate both racemic and asymmetric approaches, depending upon the choice of the allylsilane metathesis partner.

Results: The use of the allyltrimethylsilane cross-metathesis approach enables the rapid construction of the key cyclisation precursor 3 (3 steps from commercial materials), which undergoes acid-induced cyclisation to give the desired bicyclic indolizidine skeleton as a 96:4 mixture of diastereomers. Simple functional group interconversions allowed the completion of the total synthesis of racemic tashiromine in six steps (19% overall yield). Three chiral α-alkoxyallylsilanes (12, 14 and 15) were prepared in enantioenriched form and their cross-metathesis reactions studied as part of a putative asymmetric approach to tashiromine. In the event, α-hydroxysilane 12 underwent isomerisation under the reaction conditions to acylsilane 17, while silanes 14 and 15 were unreactive towards metathesis.

Conclusion: A concise, stereoselective total synthesis of racemic tashiromine has been developed. Attempts to translate this into an asymmetric synthesis have thus far been unsuccessful.

Background

Tashiromine (1) is a naturally occurring indolizidine, isolated from an Asian deciduous shrub Maackia tashiroi. [1] As one of the structurally simpler indolizidine alkaloids, [2] tashiromine has been a popular target for synthetic chemists, and to date has succumbed to total synthesis on thirteen occasions. [3-15] A wide variety of reactions have been employed to assemble the core indolizidine structure, including radical cyclisations,[3] nucleophilic addition to imines,[5,14,15] electrophilic alkylation of pyroles,[7,13] alkylation of enamines,[6] β-amino esters [8] and pyrrolidinylolithiums,[12] stereoselective reduction of enamines [4,9] and pyridinium salts; [11] and titanium-mediated reductive imide-olefin cyclisation. [10] Our own approach [14] utilises an intramolecular addition of an allylsilane to an N-acyliminium ion to deliver the [4.3.0]-azabicyclic (indolizidine) skeleton 2 (Scheme 1), wherein the pendant vinyl group acts as a handle to install the hydroxymethyl sidechain found in tashiromine. The synthesis of azabicyclic assemblies by intramolecular allylsilane/N-acyliminium cyclisations was first studied by Hiemstra and Speckamp,[16] who prepared their functionalised allylsilane cyclisation precursors (such as 3) by alkylation of cyclic imides with rea-
gent 4 (X = OMs). This, in turn, was prepared in four steps by alkylation of an acetylide anion with commercially available iodomethyltrimethylsilane, followed by partial reduction of the alkyne. Alternative synthetic approaches to 4 (X = OMs, 1) involve olefination of aldehydes using the Seyferth-Fleming phosphorane [17] or nickel-catalysed 1,2-metallate rearrangement of lithiated dihydro-pyran. [18] Our approach was informed by the prior work by our own group [19-24] and others [25-38] on the use of olefin metathesis to generate functionalised allylsilanes. Specifically, cross-metathesis of N-pentenylsuccinimide 5 with allyltrimethylsilane 6 [39] followed by chemoselective partial reduction of the imide would give the cyclisation precursor 3 in short order. Further, the use of chiral allylsilanes as cross-metathesis partners would potentially facilitate an asymmetric approach to the total synthesis of 1. We report herein full details of the successful synthesis of racemic tashiromine 1 by this strategy,[14] as well as our initial attempts towards an asymmetric variant.

Results and discussion

Metathesis precursor 5 was prepared by alkylation of the sodium salt of succinimide with 5-bromo-1-pentene in near quantitative yield (Scheme 2, see Additional File 1 for full experimental data). The key cross-metathesis reaction of 5 was carried out using a fourfold excess of allyltimethylsilane 6 and 5 mol% of Grubbs’ second generation catalyst in refluxing dichloromethane. The desired product 7 was formed in 73% yield as an inseparable 3:1 mixture of E- and Z-isomers. Partial reduction with sodium borohydride generated the cyclisation precursor 3 in 86% yield, again as a 3:1 mixture of olefin isomers. Exposure of this mixture to trifluoroacetic acid in dichloromethane at room temperature gave the bicyclic amide 2 in 85% yield as a 96:4 mixture of diastereomers. The identity of the major diastereomer was confirmed by comparison of the spectral data with those of Hiemstra:[16] specifically, the signal for the (ring-fusion) proton at C6 for the major diastereomer appeared as a doublet of triplets with 6 = 3.19 ppm, whereas the corresponding signal for the minor diastereomer appeared at 6 = 3.67 ppm. The stereochemical outcome of this reaction was rationalised on the basis of the model shown in Scheme 2, whereby nucleophilic addition of the allylsilane to the N-acyliminium ion occurs through a chair-like transition state with the nascent alkene equatorially disposed.

Scheme 2: Stereo selective construction of the indolizidine core 2

All that remained to complete the synthesis of tashiromine 1 was to effect the oxidative cleavage of the C5 vinyl substituent, then carry out a global reduction of the resulting carbonyl function and the amide. In the event, attempts to form a C5 aldehyde using either ozonolytic or dihydroxylation/periodate alkene cleavage protocols were unsuccessful, with complex mixtures being obtained in both cases. We suspected that the problem lay in the potential for the desired aldehyde to undergo retro-Mannich fragmentation, and so elected to carry out a reductive work-up to the ozonolysis procedure (Scheme 3). The desired alcohol 8 was obtained in a crude form and immediately subjected to reduction with lithium aluminium hydride to give our target tashiromine 1 in 36% yield over two steps. Our stereochemical assignment for the cyclisation of 3 was further corroborated by the agreement of the spectral data for 1 with those previously published in the literature.[3-5,9-12] Additionally, the spectral data for the diastereomeric epi-tashiromine have been reported and differ significantly from those recorded for 1.[10]

Scheme 3: Completion of the total synthesis of tashiromine 1

Having completed our target synthesis, our next goal was to investigate an asymmetric approach to tashiromine. Specifically, we envisaged that cyclisation precursors of type 9 ought to be readily available by cross-metathesis of
with an appropriate chiral allylsilane followed by chemoselective partial reduction by borohydride. Thereafter, exposure to acid would generate an \( N \)-acyliminium ion, which would cyclise through a chair-like transition state with the nascent alkenyl side-chain equatorially disposed, as in the racemic series (Figure 1). The absolute stereochemistry of the newly established asymmetric centres would be controlled by allylic strain arguments, assuming that the well-established precedent for \( \text{anti-S}_{2}^{2'} \) attack of the iminium on the allylsilane was upheld here. [40] Thus, the predicted major stereoisomer 10 would have \((5S, 6S)\) stereochemistry and an \( E \)-configured side-chain, while cyclisation to the predicted minor \((5R, 6R)\) isomer 11 would be disfavoured by \( A_{1,3} \)-interactions between the \( R_{1} \) group and vinylic proton (leading to the \( Z \)-configured side-chain). This would represent an immolative transfer of chirality approach to tashiromine, since the olefinic side-chains would be cleaved to install the hydroxymethyl side-chain required by the natural product.

Our approach centred on the readily availability of chiral \( \alpha \)-hydroxysilane 12 in enantioenriched format. [41] Protection of the hydroxyl group, either before or after cross-metathesis, would allow access to chiral allylsilanes 9 with \( R_{1} \) being an alkoxy or acyloxy group. Furthermore, this would generate products 10 and/or 11 with a readily oxidised enol-ether/ester side chain for progression to tashiromine. We were, of course, mindful that these functions could potentially act as nucleophiles themselves in the acidic medium of the electrophilic cyclisation, and the investigation of such chemoselectivity issues provided a further impetus for this study. Acylsilane 13 was therefore prepared from propargyl alcohol in four steps then subjected to asymmetric reduction with \((-\)-DIPCI according to Buynak et al (Scheme 4). [41] The desired hydroxysilane 12 was obtained in 53% yield and with 91% ee as determined by chiral HPLC analysis. Compound 12 was converted by standard methods to the acetate 14 and the tetrahydropyranyl ether 15. The latter compound was formed as a 1.3:1 mixture of diastereomers which were partially separated by column chromatography – all subsequent reactions were carried out on diastereomerically pure material for ease of analysis.

Scheme 4: Asymmetric synthesis of chiral (alkoxy)allylsilanes

With the requisite enantioenriched allylsilanes in hand, we next investigated their behaviour in olefin cross-metathesis reactions. Unfortunately, neither 14 nor 15 reacted with 5 under the standard cross-metathesis conditions used for trimethylsilane 6; the use of more forcing conditions (elevated temperature and higher catalyst loadings) did not effect the desired transformation, the only product observed being that of homodimerisation of 5 (Scheme 5).

Figure 1
Rationale for stereoselective assembly of the indolizidine core using chiral allylsilanes.
Finally, we examined the behaviour of alcohol 12 under cross-metathesis conditions. In the event, two isomerised products were isolated from this reaction (Scheme 6): the internal alkene 16 (formed in 99% yield as a ca. 3:1 mixture of E:Z isomers) and the acylsilane 17. The formation of isomerised alkenes accompanying (or instead of) metathesis processes using ruthenium-based catalysts is well documented, [42-63] as is the formation of carbonyl compounds by isomerisation of the corresponding allylic alcohols. [64-68] At this stage we therefore reluctantly abandoned our investigations into the asymmetric synthesis of tashiromine.

Scheme 5: Attempted cross-metathesis of (alkoxy)allylsilanes

58% (3:1 E:Z).

Finally, we examined the behaviour of alcohol 12 under cross-metathesis conditions. In the event, two isomerised products were isolated from this reaction (Scheme 6): the internal alkene 16 (formed in 99% yield as a ca. 3:1 mixture of E:Z isomers) and the acylsilane 17. The formation of isomerised alkenes accompanying (or instead of) metathesis processes using ruthenium-based catalysts is well documented, [42-63] as is the formation of carbonyl compounds by isomerisation of the corresponding allylic alcohols. [64-68] At this stage we therefore reluctantly abandoned our investigations into the asymmetric synthesis of tashiromine.

Conclusion

A concise, stereoselective total synthesis of racemic tashiromine has been developed (six steps from succinimide, 19% overall yield) where the key steps are the preparation of a functionalised allylsilane by olefin cross-metathesis and the construction of the indolizidine core by intramolecular addition of the allylsilane to an N-acyliminium ion. Attempts to translate this into an asymmetric synthesis utilising cross-metathesis reactions of chiral α-alkoxysilanes have thus far been unsuccessful.

Additional material

Experimental protocols for the synthesis of tashiromine 1 and the preparation of silanes 12, 14, 15 and 17 available as additional file 1.

Acknowledgements

We thank the EPSRC for a studentship (ADM) and Pfizer and Merck for generous unrestricted research funding.

References

1. Ohmiya S, Kubo H, Otomaru H, Saito K, Murakoshi I: Heterocycles 1990, 30:537-542.
2. Michael JP: Natural Product Reports 2007, 24:191-222. and references therein.
3. Beckwith ALJ, Westwood SW: Tetrahedron 1989, 45:5269-5282.
4. Haddad M, Celerier JP, Haviari G, Lhommet G, Dhimane H, Pompelet JC, Chuche J: Heterocycles 1990, 31:1251-1260.
5. Nagao Y, Dal W-M, Ochiai M, Tsukagoshi S, Fujita E: J Org Chem 1990, 55:1148-1156.
6. Paulvannan K, Stille JR: J Org Chem 1994, 59:1613-1620.
7. Gage JL, Branchaud BP: Tetrahedron Lett 1997, 38:7007-7010.
8. Ha D-C, Park S-H, Choi K-S, Yun C-S: Bull Korean Chem Soc 1998, 19:728-730.
9. David O, Blox J, Bellec C, Fargeau-Bellassoued M-C, Haviari G, Celerier J-P, Lhommet G, Gramain J-C, Gardette D: J Org Chem 1999, 64:3122-3131.
10. Kim S-H, Kim SI, Lai S, Cha JK: J Org Chem 1999, 64:6771-6775.
11. Bates RW, Boonsombat J: J Chem Soc, Perkin Trans 1 2001, 654-656.
12. Dieter RK, Watson R: Tetrahedron Lett 2002, 43:7725-7728.
13. Banwell MG, Beck DAS, Smith JA: Tetrahedron Lett 2004, 1:157-159.
14. McElhinney AD, Marsden SP, Synlett 2005:2528-2530.
15. Belanger M, Larouche-Gauthier R, Menard F, Nantel M, Barabe F: J Org Chem 2006, 71:704-712.
16. Hiemstra H, Sno MHAM, Vijn RJ, Speckamp WN: J Org Chem 1985, 50:4014-4020.
17. Paquette LA, Mendez-Andino JL: J Org Chem 1999, 63:9061-9068.
18. Bergmeier SC, Seth PP: J Org Chem 1997, 62:2671-2674.
19. Cassidy JH, Marsden SP, Synlett 1997:1411-1413.
20. Miles SM, Marsden SP, Leatherbarrow RJ, Coates WJ: J Org Chem 2004, 69:6874-6882.
21. Miles SM, Marsden SP, Leatherbarrow RJ, Coates WJ: J Chem Commun 2004:2292-2293.
22. Akinede T, Marsden SP, Cumming JG: Org Lett 2005, 7:3685-3688.
23. Akinede T, Marsden SP, Cumming JG: Tetrahedron Lett 2005, 46:7235-7238.
24. Cassidy JH, Farting CN, Marsden SP, Pedersen A, Slater M, Stemp G: J Org Chem 2006, 71:4118-4126.
25. Teare H, Huguet F, Tredwell M, Thibaudeau S, Luthra S, Gouverneur V: ARKIVOC 2002:232-244 [http://www.arkivoc.org/ARKIVOC/JOURNAL_CONTENT/manuscripts/2002/AK-2285GSP] as published main manuscript.pdf]
26. Thibaudeau S, Gouverneur V: Org Lett 2003, 5:4891-4893.
27. Alvarez Corral M, Lopez Sanchez C, Jimenez Gonzalez L, Rosales A, Munoz Dorado M, Rodriguez Garcia I: Beilstein J Org Chem 2007:3.
28. Jimenez Gonzalez L, Garcia Munoz S, Alvarez Corral M, Munoz Dorado M, Rodriguez Garcia I: J Org Chem 2007, 72:557-568.
29. Jimenez Gonzalez L, Garcia Munoz S, Alvarez Corral M, Munoz Dorado M, Rodriguez Garcia I: J Org Chem 2006, 71:8762-8769.
30. Garcia Munoz S, Jimenez Gonzalez L, Alvarez Corral M, Munoz Dorado M, Rodriguez Garcia I: J Chem Comm 2005:2689-2691.
33. He A, Yan B, Thanavaro A, Spilling CD, Rath NP: J Org Chem 2004, 69:8643-8651.
34. BouzBouz S, De Lemos E, Cossy J: Adv Synth Cat 2002, 344:627-630.
35. Meyer C, Cossy J: Tetrahedron Lett 1997, 38:7861-7864.
36. Taylor RE, Engelhardt FC, Schmitt MJ, Yuan H: J Am Chem Soc 2001, 123:2964-2969.
37. Taylor RE, Engelhardt FC, Yuan H: Org Lett 1999, 1:257-1260.
38. Chang SB, Grubbs RH: Tetrahedron Lett 1997, 38:4757-4760.
39. Crowe WE, Goldberg DR, Zhang ZJ: Tetrahedron Lett 1996, 37:2117-2120.
40. Fleming I, Barbero A, Walter D: Chem Rev 1997, 97:2063-2192.
41. Buynak JD, Strickland JB, Lamb GW, Khansis D, Modi S, Williams D, Zhang H: J Org Chem 1991, 56:7076-7083.
42. Miller SJ, Blackwell HE, Grubbs RH: J Am Chem Soc 1996, 118:9606-9614.
43. Hoye TR, Promo MA: Tetrahedron Lett 1999, 40:1429-1432.
44. Massmann HD, Grubbs RH: Tetrahedron Lett 1999, 40:1317-1340.
45. Edwards SD, Lewis T, Taylor RJ, Taylor RJ: Tetrahedron Lett 1999, 40:4267-4270.
46. Furstner A, Thiel OR, Ackermann L, Schanz H-J, Nolan SP: J Org Chem 2000, 65:2204-2207.
47. Cadot C, Dalko PI, Cossy J: Tetrahedron Lett 2002, 43:1839-1841.
48. Arisawa M, Terada Y, Nakagawa M, Nishida A: Angew Chem, Int Ed 2002, 41:4732-4734.
49. Sutton AE, Seigel BA, Finnegan DF, Snapper ML: J Am Chem Soc 2002, 124:13390-13391.
50. Wipf P, Rector SR, Takahashi H: J Am Chem Soc 2002, 124:14848-14849.
51. Schmidt B: Eur J Org Chem 2003, 68:816-819.
52. Sworen JC, Pawlow JH, Case W, Lever J, Wagener KB: J Mol Cat A 2003, 194:69-78.
53. Lehman SE, Schwendeman JE, O'Donnell PM, Wagener KB: Inorg Chim Acta 2003, 345:190-198.
54. Peczu MW, Snyder NL: Tetrahedron Lett 2003, 44:4057-4061.
55. Alcaide B, Almendros P, Alonso JM: Chem Eur J 2003, 9:5793-5799.
56. Kotha S, Mandal K: Tetrahedron Lett 2004, 45:1391-1394.
57. Schmidt B: J Org Chem 2004, 69:7672-7687.
58. Hong SH, Sanders DP, Lee CW, Grubbs RH: J Am Chem Soc 2005, 127:17160-17161.
59. Bennasar ML, Roca T, Monerris M, Garcia-Diaz D: J Org Chem 2006, 71:7028-7034.
60. Hansen J, Giroux S, Larsson A: Org Lett 2006, 8:5481-5484.
61. Courchay FC, Sworen JC, Ghiviriga I, Abboud KA, Wagener KB: Organometallics 2006, 25:6074-6086.
62. Raju R, Allen LJ, Le T, Taylor CD, Howell AR: Org Lett 2007, 9:1699-1701.
63. Moiese J, Arseniyadis S, Cossy J: Org Lett 2007, 9:1695-1698.
64. Gurjar MK, Yakubram P: Tetrahedron Lett 2001, 42:3633-3636.
65. Greenwood ES, Parsons PJ, Young MJ: Synth Commun 2003, 33:223-228.
66. Werner H, Grunwald C, Stuer W, Wolf C: Organometallics 2003, 22:1558-1560.
67. Edlin CD, Faulkner J, Fergus D, Knight CK, Parker J, Preece I, Quayle P, Richards SN: Synlett 2005:572-576.
68. Finnegan D, Seigal BA, Snapper ML: Org Lett 2006, 8:2603-2606.